Color?s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions. Between them, cancer and heart disease constitute the two biggest causes of death worldwide. In September 2018, we introduced a new health area, medication response, to help people understand how their genes may influence response to certain medications. By combining state-of-the-art software with clinical genomics, we?re building a personal health service that helps people benefit from the information in their own bodies. Early detection helps individuals create preventative plans with their doctors using appropriate screening guidelines relative to their personal and familial risk of certain diseases including cancer and heart disease. We?re an early stage company making a huge impact in people?s lives. We?ve built a best in class team from Google, Dropbox, Pinterest and Twitter. Our product work is uniquely interdisciplinary - teams include scientists, doctors, designers, robotics engineers, and PMs. Lastly, we?re empowered by amazing investors including General Catalyst, Khosla Ventures, Sundar Pichai, Laurene Powell-Jobs, Aaron Levie and Padmasree Warrior.

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.